Literature DB >> 21339346

Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.

Alampady K Shanbhogue1, Srinivasa R Prasad, Naoki Takahashi, Raghunandan Vikram, Dushyant V Sahani.   

Abstract

Focal nodular hyperplasia (FNH), hepatocellular adenoma (HCA), and hepatocellular carcinoma (HCC) compose hepatocellular neoplasms that occur in adults. These tumors demonstrate characteristic epidemiologic and histopathologic features and clinical and imaging manifestations. HCAs are monoclonal neoplasms characterized by increased predilection to hemorrhage or rupture and occasional transformation to HCC. On the other hand, FNH is a polyclonal tumorlike lesion that occurs in response to increased perfusion and has an indolent clinical course. Up to 90% of HCCs occur in the setting of cirrhosis. Chronic viral hepatitis (hepatitis B and hepatitis C) infection and metabolic syndrome are major risk factors that can induce HCCs in nonfibrotic liver. Recent advances in pathology and genetics have led to better understanding of the histogenesis, natural history, and molecular events that determine specific oncologic pathways used by these neoplasms. HCAs are now believed to result from specific genetic mutations involving TCF1 (transcription factor 1 gene), IL6ST (interleukin 6 signal transducer gene), and CTNNB1 (β catenin-1 gene); FNHs are characterized by an "imbalance" of angiopoietin. While the β catenin signaling pathway is associated with well- and moderately differentiated HCCs, mutations involving p53 (tumor protein 53 gene), MMP14 (matrix metalloproteinase 14 gene), and RhoC (Ras homolog gene family, member C) are associated with larger tumor size, higher tumor grade with resultant shortened tumor-free survival, and poor prognosis. Fibrolamellar carcinoma (FLC), a unique HCC subtype, exhibits genomic homogeneity that partly explains its better overall prognosis. On the basis of recent study results involving cytogenetics and oncologic pathways of HCCs, novel drugs that act against molecular targets are being developed. Indeed, sorafenib (a multikinase inhibitor) is currently being used in the successful treatment of patients with advanced HCC. Characterization of genetic abnormalities and genotype-phenotype correlations in adult hepatocellular tumors provides better understanding of tumor pathology and biology, imaging findings, prognosis, and response to molecular therapeutics. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339346     DOI: 10.1148/radiol.10100376

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

1.  Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree.

Authors:  Annarita Pecchi; Giulia Besutti; Mario De Santis; Cinzia Del Giovane; Sofia Nosseir; Giuseppe Tarantino; Fabrizio Di Benedetto; Pietro Torricelli
Journal:  World J Hepatol       Date:  2015-02-27

2.  Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma.

Authors:  Wei Huang; Fei Gao; Kang Li; Wen Wang; Ya-Rou Lai; Shao-Hui Tang; Dong-Hua Yang
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

3.  Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.

Authors:  Timm Denecke; Ingo G Steffen; Sheela Agarwal; Daniel Seehofer; Thomas Kröncke; Enrique Lopez Hänninen; Incken-Birthe Kramme; Peter Neuhaus; Sanjay Saini; Bernd Hamm; Christian Grieser
Journal:  Eur Radiol       Date:  2012-03-22       Impact factor: 5.315

Review 4.  New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies.

Authors:  Shuo Yang; Liang Yang; Xinyu Li; Bowen Li; Yan Li; Xiaodong Zhang; Yingbo Ma; Xueqiang Peng; Hongyuan Jin; Hangyu Li
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

Review 5.  Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma.

Authors:  William Matthew Puszyk; Thu Le Trinh; Sarah J Chapple; Chen Liu
Journal:  Lab Invest       Date:  2013-08-05       Impact factor: 5.662

Review 6.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

7.  A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization.

Authors:  Ali Morshid; Khaled M Elsayes; Ahmed M Khalaf; Mohab M Elmohr; Justin Yu; Ahmed O Kaseb; Manal Hassan; Armeen Mahvash; Zhihui Wang; John D Hazle; David Fuentes
Journal:  Radiol Artif Intell       Date:  2019-09-25

8.  Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.

Authors:  Lingli Li; Xuefeng Kan; Yongjun Zhao; Bo Liang; Tianhe Ye; Lian Yang; Chuansheng Zheng
Journal:  Int J Med Sci       Date:  2021-03-30       Impact factor: 3.738

Review 9.  That liver lesion on MDCT in the oncology patient: is it important?

Authors:  Richard M Gore; Kiran H Thakrar; Daniel R Wenzke; Geraldine M Newmark; Uday K Mehta; Jonathan W Berlin
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

10.  Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification.

Authors:  Charles Balabaud; Wesal R Al-Rabih; Pei-Jer Chen; Kimberley Evason; Linda Ferrell; Juan C Hernandez-Prera; Shiu-Feng Huang; Thomas Longerich; Young Nyun Park; Alberto Quaglia; Peter Schirmacher; Christine Sempoux; Swan N Thung; Michael Torbenson; Aileen Wee; Matthew M Yeh; Shiou-Hwei Yeh; Brigitte Le Bail; Jessica Zucman-Rossi; Paulette Bioulac-Sage
Journal:  Int J Hepatol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.